Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Palisade Bio, Inc.

NASDAQ: PALI · Life Sciences · 3 alerts · CIK 1357459

Share price
$1.03Close, Nov 16
Market cap
$185M
Shares outstanding
179.28MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Palisade Bio, Inc. filings on SEC EDGAR ↗

4:23 PM ET 8-K
Financial Results

Palisade Bio Financial Results

Palisade Bio reported third quarter 2026 financial results and provided a clinical update on its PALI-2108 programs, including the initiation of the Phase 2b ASCENTRA-UC trial. The company ended the quarter with $113.6 million in cash and expects topline results from the UC trial in Q4 2027.

“ASCENTRA-UC is now underway, and our focus is on driving enrollment and executing the study to deliver topline results in the fourth quarter of 2027. With nearly all planned U.S. sites activated, we are expanding our global clinical footprint to build on that progress.”

JD Finley, Chief Executive Officer of Palisade Bio

“In parallel, we are preparing to initiate ASCENTRA-CD, with initiation of enrollment targeted for the first quarter of 2027. Our strong financial position supports execution across both programs as we work to establish PALI-2108’s potential as a differentiated, once-daily oral treatment for patients living with IBD.”

JD Finley, Chief Executive Officer of Palisade Bio
4:08 PM ET 10-Q
Financial Results

Palisade Bio Q3 2026 Results: Net Loss of $14.6M, Loss Widens

Palisade Bio reported a net loss of $34.8 million for the nine months ended September 30, 2026, compared to $7.9 million in the prior year, driven by a significant increase in research and development expenses. The company maintained a cash position of $113.6 million and generated $0.5 million in license revenue during the period.

Key figure
Net loss $14.6M

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.